<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3194560</article-id><article-id pub-id-type="publisher-id">1546-0096-9-S1-P201</article-id><article-id pub-id-type="doi">10.1186/1546-0096-9-S1-P201</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Horneff</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>g.horneff@asklepios.com</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Fitter</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Huppertz</surname><given-names>HI</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Foeldvari</surname><given-names>I</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Kuemmerle-Deschner</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Kuester</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Tzaribacev</surname><given-names>N</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Thon</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Borte</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Ganser</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Trauzeddel</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Minden</surname><given-names>K</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib></contrib-group><aff id="I1"><label>1</label>Asklepios Clinic, Sankt Augustin, Germany</aff><aff id="I2"><label>2</label>Prof Hess Children's Hospital, Bremen, Germany</aff><aff id="I3"><label>3</label>Paediatric Rheumatology Office, Hamburg, Germany</aff><aff id="I4"><label>4</label>University Tuebingen, Tuebingen, Germany</aff><aff id="I5"><label>5</label>Centre Paediatric Rheumatology, Bad Bramstedt, Germany</aff><aff id="I6"><label>6</label>Paediatric Rheumatology Centre, Bad Bramstedt, Germany</aff><aff id="I7"><label>7</label>MMH Hannover, Hannover, Germany</aff><aff id="I8"><label>8</label>St. Georgs Hospital, Leipzig, Germany</aff><aff id="I9"><label>9</label>Paeditric Rheumatology Centre, Sendenhorst, Germany</aff><aff id="I10"><label>10</label>Helios Clinics, Berlin, Germany</aff><aff id="I11"><label>11</label>Charite, Berlin, Germany</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2011</year></pub-date><volume>9</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress</named-content><named-content content-type="supplement-editor">Johannes Roth, Alberto Martini, Michael Hofer, Marco Gattorno, Hermann Girschick, Pierre Quartier, Carlos Rose, Rebecca ten Cate, Rolando Cimaz, Pavla Dolezalova, Sue Maillard and Carine Wouters</named-content></supplement><fpage>P201</fpage><lpage>P201</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Horneff et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Horneff et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/9/S1/P201"/><conference><conf-date>14-18 September 2011</conf-date><conf-name>18th Pediatric Rheumatology European Society (PReS) Congress</conf-name><conf-loc>Bruges, Belgium</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>TNF-inhibitors are valuable treatment options for adult AS but are not approved for juvenile AS.</p></sec><sec><title>Aim</title><p>To determine efficacy of adalimumab (ADA) in juvenile AS in a 12 wks double blind placebo controlled trial.</p></sec><sec sec-type="methods"><title>Methods</title><p>In total 32 subjects aged from 12 to 17 years suffering from juvenile AS were enrolled into the clinical trial HUM06-037. All subjects were randomized and included in the ITT analysis, among them 2 who terminated the treatment prematurely after 3 injections due to insufficient efficacy (one of each group) and were label as non-responders.</p></sec><sec><title>Results</title><p>17 patients were randomized to receive ADA 40mg/2wks and 15 patients received placebo. Stable doses of NSAIDs and low dose of corticosteroids (&#x02264;10 mg per day) were permitted. In the ADA group a decrease of all disease activity parameters was noted at wk 12: BASDAI spinal inflammation score -66% (p&#x0003c;0.001); back pain score -48% (p&#x0003c;0.005); BASFI score -47 % (p&#x0003c;0.02); CHAQ-DI score -65% (p&#x0003c;0.005); ESR -75% (p&#x0003c;0.05) and finally the CRP - 80% (p=0.07).</p><p>ASAS20 and 40 response rates after 4, 8 and 12 weeks were higher on ADA than in the PLC group (table <xref ref-type="table" rid="T1">1</xref>)</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>per protocol analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">ASAS20</th><th align="left" colspan="3">ASAS40</th></tr></thead><tbody><tr><td align="left">Wk.</td><td align="left">PLC</td><td align="left">ADA</td><td align="left">p</td><td align="left">PLC</td><td align="left">ADA</td><td align="left">p</td></tr><tr><td align="left">4</td><td align="left">4 (31%)</td><td align="left">9 (56%)</td><td align="left">0.24</td><td align="left">3 (23%)</td><td align="left">7 (44%)</td><td align="left">0.19</td></tr><tr><td align="left">8</td><td align="left">3 (23%)</td><td align="left">10 (63%)</td><td align="left">0.03*</td><td align="left">3 (23%)</td><td align="left">9 (56%)</td><td align="left">0.07</td></tr><tr><td align="left">12</td><td align="left">4 (31%)</td><td align="left">9 (63%)</td><td align="left">0.17</td><td align="left">4 (31)</td><td align="left">9 (56%)</td><td align="left">0.17</td></tr></tbody></table></table-wrap><p>During the 12 wks controlled phase 26 AEs occurred in 10 pts. on PLC compared to 25 AEs in 11 pts on ADA. Injection site reactions were the most common adverse event (10 on PLC, 11 on ADA). There were 16 various infections occurring in the double blind phase, 6 on PLC, 10 on ADA. 2 SAEs occurred on ADA.</p></sec><sec><title>Conclusions</title><p>This small placebo controlled trial demonstrated significant effects of adalimumab treatment in patients with juvenile ankylosing spondylitis.</p></sec></body></article>